Literature DB >> 8873593

A zinc binding site in viral serine proteinases.

R De Francesco1, A Urbani, M C Nardi, L Tomei, C Steinkühler, A Tramontano.   

Abstract

The NS3 protein of hepatitis C virus contains a chymotrypsin-like serine proteinase domain. We built a homology model of this domain which predicts the presence of a tetradentate metal binding site formed by three cysteines and one histidine. These residues are strictly conserved in all known hepatitis C viral genotypes as well as in other recently discovered related hepatitis viruses. We show that the hepatitis C virus enzyme does indeed contain a Zn2+ ion with S3N ligation and that the metal is required for structural integrity and activity of the enzyme. Strikingly, the residues forming the metal binding site are also conserved in the chymotrypsin-like 2A cysteine proteinases of picornaviruses. Remarkably, in these highly variable viral genomes the metal binding site is more conserved than the catalytic residues and thus allows us to define a novel class of zinc binding chymotrypsin-like proteinases and to identify a new attractive target for antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873593     DOI: 10.1021/bi9616458

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  20 in total

1.  Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.

Authors:  G Barbato; D O Cicero; F Cordier; F Narjes; B Gerlach; S Sambucini; S Grzesiek; V G Matassa; R De Francesco; R Bazzo
Journal:  EMBO J       Date:  2000-03-15       Impact factor: 11.598

2.  Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease.

Authors:  T Ueno; S Misawa; Y Ohba; M Matsumoto; M Mizunuma; N Kasai; K Tsumoto; I Kumagai; H Hayashi
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Molecular characterization of a full genome Turkish hepatitis C virus 1b isolate (HCV-TR1): a predominant viral form in Turkey.

Authors:  Esra Yildiz; Asli Oztan; Funda Sar; Ergun Pinarbasi; Rengul Cetin-Atalay; Hikmet Akkiz; Mehmet Ozturk
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

Review 4.  Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target.

Authors:  Kevin D Raney; Suresh D Sharma; Ibrahim M Moustafa; Craig E Cameron
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

5.  Conformational stability of hepatitis C virus NS3 protease.

Authors:  Olga Abian; Sonia Vega; Jose Luis Neira; Adrian Velazquez-Campoy
Journal:  Biophys J       Date:  2010-12-01       Impact factor: 4.033

6.  Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form.

Authors:  Y Yan; Y Li; S Munshi; V Sardana; J L Cole; M Sardana; C Steinkuehler; L Tomei; R De Francesco; L C Kuo; Z Chen
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

7.  GB virus B and hepatitis C virus NS3 serine proteases share substrate specificity.

Authors:  E Scarselli; A Urbani; A Sbardellati; L Tomei; R De Francesco; C Traboni
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

8.  Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein.

Authors:  M Pallaoro; A Lahm; G Biasiol; M Brunetti; C Nardella; L Orsatti; F Bonelli; S Orrù; F Narjes; C Steinkühler
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

9.  Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric sindbis viruses.

Authors:  G Filocamo; L Pacini; C Nardi; L Bartholomew; M Scaturro; P Delmastro; A Tramontano; R De Francesco; G Migliaccio
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus.

Authors:  P Gallinari; D Brennan; C Nardi; M Brunetti; L Tomei; C Steinkühler; R De Francesco
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.